Abstract
Purpose :
Controversy exists regarding to achieve a faster and better outcome after a central serous chorioretinopathy (CSC). We perform a pilot study to compare the efficacy of intravitreal bevacizumab plus brinzolamide versus intravitreal bevacizumab for CSC.
Methods :
Patients diagnosed with CSC were recruited from July to October 2015, of any age and sex, without prior treatment or other ocular pathology. They were divided randomly into 3 groups: group 1 = intravitreal bevacizumab, group 2 = topical brinzolamide bid for 2 weeks followed by intravitreal bevacizumab, group 3 = brinzolamide bid for 4 weeks; we analyze the following variables: sex, age, initial BCVA and the primary outcomes variables: final best corrected visual acuity (BCVA, expressed in LogMAR) and central foveal thickness (CFT, in µm) measured by SD-OCT at baseline and at 4 weeks.
Results :
We analyze 35 patients using ANOVA for 3 treatment groups, we found 77.1% were male and 51.4% had involvement of the right eye. Group 1 n=12 patients, group 2 n=12 patients, group 3 n=11. The age range was from 22 to 65 years, with an average age of 38+11.3. An initial average of uncorrected visual acuity (LogMAR) of 0.329 in group 1, 0.409 in group 2, 0.410 in group 3 (p = 0.794). We found a statistically significant difference in group 1 (Bevacizumab) between the initial and final BCVA (LogMAR) with an improvement in the average of -0.100 (p = 0.002), the final CFT average obtained were: group 1= 286.7±57.4, group 2= 296.1±61.9, group 3= 283.3±30.8; this results were similar in 3 groups and statistically different from initial CFT (p=0.000, p=0.000 and p=0.008 respectively).
Conclusions :
We found statistically significant difference in the final BCVA in the bevacizumab group, towards a better final BCVA in group 1, however 3 groups had good final BCVA and CFT.
This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.